ARGX vs NVS
argenx SE vs Novartis AG — AI-powered side-by-side comparison
| Metric | ARGX | NVS |
|---|
| AI Score |
69
|
75
|
| Price |
$864.40
|
$154.64
|
| P/E Ratio |
31.34×
|
23.55×
|
| ROE |
17.6%
|
30.5%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
89.9%
|
74.3%
|
| Debt / Equity |
0.01×
|
1.18×
|
| Dividend Yield |
0.0%
|
2.9%
|
| RSI (14) |
47.9
|
57.7
|
| Beta |
-0.022
|
0.462
|
| Expected Upside |
—
|
+2.4%
|
AI Committee View
Current Innellis committee reasoning for ARGX versus NVS.
NVS leads by 6 points.
NVS scores 75/100 (Buy) versus ARGX at 69/100 (Buy).
ARGX Committee View
67% agreement
6 analysts
The primary driver is revenue growing 71.3% yoy -- genuine top-line momentum. The main limiting factor is price-to-book of 6.9x prices in significant intangible value. The committee is constructive but not yet at full conviction.
Bull Case
- ROE of 22.4% shows genuine earnings power backing the valuation — Value
- Revenue growing 71.3% YoY -- genuine top-line momentum — Growth
- EPS growing 95.7% YoY — Growth
Bear Case
- Price-to-book of 6.9x prices in significant intangible value — Value
- MACD histogram negative -- bearish momentum — Technical
NVS Committee View
100% agreement
5 analysts
The primary driver is quarter-over-quarter growth rate is accelerating, not just positive. The main limiting factor is 2 existing position pair(s) are highly correlated already. The committee is constructive but not yet at full conviction.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
Bear Case
- MACD histogram negative -- bearish momentum — Technical